Philadelphia, PA and New York, NY – DrugDev and Citeline, part of Informa’s Pharma Intelligence vertical, announced today that the two companies have integrated data from Citeline’s Trialtrove and Sitetrove intelligence platforms with the DrugDev Spark unified clinical operations suite. Indexing information captured by Citeline on more than 390,000 investigators across over 265,000 trials in more than 170 countries to the industry-standard DrugDev Golden Number adds significantly to the amount of information available for study planning and site identification through DrugDev Spark.
By incorporating data from Citeline into DrugDev Spark, mutual Citeline and DrugDev biopharma clients can now easily and efficiently identify the ideal sites at which to conduct their clinical trials. In addition, clients using DrugDev Spark will be able to seamlessly move from study planning and site identification to other proven solutions such as site activation, site payments, eConsent, learning management, document exchange, site engagement and more.
This significant collaboration allows Informa’s Pharma Intelligence vertical’s clients who subscribe to both Trialtrove and Sitetrove system via XML feed and who are also clients of DrugDev to access a broader range of data sources. By integrating key Citeline data components into the DrugDev Spark study planning and site identification toolset, users can simplify the once arduous task of having to utilize multiple resources to research clinical trial investigators at high performing sites for their own clinical studies.
Citeline clients participating in the Investigator Databank or TransCelerate’s Investigator Registry collaboration, for example, will now have the ability to see data from: online profiles, their own CTMS, other member’s CTMS, the DrugDev network, clinicaltrials.gov, and Citeline’s Trialtrove and Sitetrove.
“We are excited to be working with DrugDev for our mutual clients’ benefit in improving the speed and success of clinical drug development. Our customers need data, together with technology, to deliver new and innovative drugs into the pharmaceutical market. We look forward to furthering the relationship with DrugDev to assist our customers in achieving that goal,’ said Linda Blackerby, President of Informa Pharma Intelligence.
Combining all available data assets into one single view increases the breadth of evidence available to encompass data from both public and private domains. This in turn enables both faster and better decision-making by considering all information in a single query as opposed to the current practice of running queries in multiple systems and having to consolidate results to understand the full landscape for the study.
Elisa Cascade, President, Data Solutions at DrugDev, explained, “Informa has a reputation for excellence in pharma intelligence among the global pharma community. We are excited to partner with Informa because we are committed to making it easier and more expedient for pharma and biotech organizations to conduct more clinical trials. By integrating data in one trusted location, we can now simplify the evidence-based planning and site identification process for our customers through access to a single integrated view of data from all available sources – enabling sponsors to make better site selection decisions, faster.”
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.